5pzf - Revision history

OCA at 13:28, 6 March 2024

OCA — Wed, 06 Mar 2024 13:28:20 GMT

←Older revision		Revision as of 13:28, 6 March 2024
Line 10:		Line 10:
	== Function ==		== Function ==
	[https://www.uniprot.org/uniprot/SP100_HUMAN SP100_HUMAN] Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation.<ref>PMID:11909962</ref> <ref>PMID:14647468</ref> <ref>PMID:15247905</ref> <ref>PMID:15592518</ref> <ref>PMID:15767676</ref> <ref>PMID:16177824</ref> <ref>PMID:17245429</ref> <ref>PMID:21274506</ref> <ref>PMID:21880768</ref>		[https://www.uniprot.org/uniprot/SP100_HUMAN SP100_HUMAN] Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation.<ref>PMID:11909962</ref> <ref>PMID:14647468</ref> <ref>PMID:15247905</ref> <ref>PMID:15592518</ref> <ref>PMID:15767676</ref> <ref>PMID:16177824</ref> <ref>PMID:17245429</ref> <ref>PMID:21274506</ref> <ref>PMID:21880768</ref>
-	<div style="background-color:#fffaf0;">
-	== Publication Abstract from PubMed ==
-	In macromolecular crystallography, the rigorous detection of changed states (for example, ligand binding) is difficult unless signal is strong. Ambiguous ('weak' or 'noisy') density is experimentally common, since molecular states are generally only fractionally present in the crystal. Existing methodologies focus on generating maximally accurate maps whereby minor states become discernible; in practice, such map interpretation is disappointingly subjective, time-consuming and methodologically unsound. Here we report the PanDDA method, which automatically reveals clear electron density for the changed state-even from inaccurate maps-by subtracting a proportion of the confounding 'ground state'; changed states are objectively identified from statistical analysis of density distributions. The method is completely general, implying new best practice for all changed-state studies, including the routine collection of multiple ground-state crystals. More generally, these results demonstrate: the incompleteness of atomic models; that single data sets contain insufficient information to model them fully; and that accuracy requires further map-deconvolution approaches.
-
-	A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density.,Pearce NM, Krojer T, Bradley AR, Collins P, Nowak RP, Talon R, Marsden BD, Kelm S, Shi J, Deane CM, von Delft F Nat Commun. 2017 Apr 24;8:15123. doi: 10.1038/ncomms15123. PMID:28436492<ref>PMID:28436492</ref>
-
-	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	</div>
-	<div class="pdbe-citations 5pzf" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 14:27, 24 January 2024

OCA — Wed, 24 Jan 2024 14:27:05 GMT

←Older revision		Revision as of 14:27, 24 January 2024
Line 3:		Line 3:
	<StructureSection load='5pzf' size='340' side='right'caption='[[5pzf]], [[Resolution\|resolution]] 1.84Å' scene=''>		<StructureSection load='5pzf' size='340' side='right'caption='[[5pzf]], [[Resolution\|resolution]] 1.84Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5pzf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5PZF OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5PZF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5pzf]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5PZF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5PZF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.84Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5pzf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5pzf OCA], [~~http~~://pdbe.org/5pzf PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5pzf RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5pzf PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5pzf ProSAT]</span></td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5pzf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5pzf OCA], [https://pdbe.org/5pzf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5pzf RCSB], [https://www.ebi.ac.uk/pdbsum/5pzf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5pzf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/SP100_HUMAN SP100_HUMAN]] Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation.<ref>PMID:11909962</ref> <ref>PMID:14647468</ref> <ref>PMID:15247905</ref> <ref>PMID:15592518</ref> <ref>PMID:15767676</ref> <ref>PMID:16177824</ref> <ref>PMID:17245429</ref> <ref>PMID:21274506</ref> <ref>PMID:21880768</ref>	+	[https://www.uniprot.org/uniprot/SP100_HUMAN SP100_HUMAN] Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation.<ref>PMID:11909962</ref> <ref>PMID:14647468</ref> <ref>PMID:15247905</ref> <ref>PMID:15592518</ref> <ref>PMID:15767676</ref> <ref>PMID:16177824</ref> <ref>PMID:17245429</ref> <ref>PMID:21274506</ref> <ref>PMID:21880768</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 23:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Arrowsmith~~, C H~~]]	+	[[Category: Arrowsmith CH]]
-	[[Category: Bountra, C]]	+	[[Category: Bountra C]]
-	[[Category: Bradley~~, A R~~]]	+	[[Category: Bradley AR]]
-	[[Category: Brandao-Neto, J]]	+	[[Category: Brandao-Neto J]]
-	[[Category: Brennan~~, P E~~]]	+	[[Category: Brennan PE]]
-	[[Category: Collins, P]]	+	[[Category: Collins P]]
-	[[Category: Cox, O]]	+	[[Category: Cox O]]
-	~~[[Category: Delft, F von~~]]	+	[[Category: Dias A]]
-	[[Category: Dias, A]]	+	[[Category: Douangamath A]]
-	[[Category: Douangamath, A]]	+	[[Category: Edwards A]]
-	[[Category: Edwards, A]]	+	[[Category: Fairhead M]]
-	[[Category: Fairhead, M]]	+	[[Category: Krojer T]]
-	[[Category: Krojer, T]]	+	[[Category: MacLean E]]
-	[[Category: MacLean, E]]	+	[[Category: Ng J]]
-	[[Category: Ng, J]]	+	[[Category: Pearce NM]]
-	[[Category: Pearce~~, N M~~]]	+	[[Category: Renjie Z]]
-	[[Category: Renjie, Z]]	+	[[Category: Sethi R]]
-	[[Category: Sethi, R]]	+	[[Category: Talon R]]
-	[[Category: Talon, R]]	+	[[Category: Wright N]]
-	[[Category: Wright, N]]	+	[[Category: Von Delft F]]
-	[[Category: ~~Bromodomain]]~~	+
-	~~[[Category: Epigenetic]]~~	+
-	~~[[Category: Pandda]]~~	+
-	~~[[Category: Sgc - diamond i04-1 fragment screening]]~~	+
-	~~[[Category: Transcription]]~~	+
-	~~[[Category: Xchemexplorer~~]]	+

OCA at 07:53, 2 September 2020

OCA — Wed, 02 Sep 2020 07:53:51 GMT

←Older revision		Revision as of 07:53, 2 September 2020
Line 1:		Line 1:

	==PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)==		==PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)==
-	<StructureSection load='5pzf' size='340' side='right' caption='[[5pzf]], [[Resolution\|resolution]] 1.84Å' scene=''>	+	<StructureSection load='5pzf' size='340' side='right'caption='[[5pzf]], [[Resolution\|resolution]] 1.84Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5pzf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5PZF OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5PZF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5pzf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5PZF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5PZF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5pzf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5pzf OCA], [http://pdbe.org/5pzf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5pzf RCSB], [http://www.ebi.ac.uk/pdbsum/5pzf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5pzf ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5pzf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5pzf OCA], [http://pdbe.org/5pzf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5pzf RCSB], [http://www.ebi.ac.uk/pdbsum/5pzf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5pzf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 22:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Arrowsmith, C H]]		[[Category: Arrowsmith, C H]]
	[[Category: Bountra, C]]		[[Category: Bountra, C]]

OCA at 09:07, 4 October 2017

OCA — Wed, 04 Oct 2017 09:07:52 GMT

←Older revision		Revision as of 09:07, 4 October 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5pzf is ~~ON HOLD~~	+	==PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)==
		+	<StructureSection load='5pzf' size='340' side='right' caption='[[5pzf]], [[Resolution\|resolution]] 1.84Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5pzf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5PZF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5PZF FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5pzf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5pzf OCA], [http://pdbe.org/5pzf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5pzf RCSB], [http://www.ebi.ac.uk/pdbsum/5pzf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5pzf ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/SP100_HUMAN SP100_HUMAN]] Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53-mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation.<ref>PMID:11909962</ref> <ref>PMID:14647468</ref> <ref>PMID:15247905</ref> <ref>PMID:15592518</ref> <ref>PMID:15767676</ref> <ref>PMID:16177824</ref> <ref>PMID:17245429</ref> <ref>PMID:21274506</ref> <ref>PMID:21880768</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	In macromolecular crystallography, the rigorous detection of changed states (for example, ligand binding) is difficult unless signal is strong. Ambiguous ('weak' or 'noisy') density is experimentally common, since molecular states are generally only fractionally present in the crystal. Existing methodologies focus on generating maximally accurate maps whereby minor states become discernible; in practice, such map interpretation is disappointingly subjective, time-consuming and methodologically unsound. Here we report the PanDDA method, which automatically reveals clear electron density for the changed state-even from inaccurate maps-by subtracting a proportion of the confounding 'ground state'; changed states are objectively identified from statistical analysis of density distributions. The method is completely general, implying new best practice for all changed-state studies, including the routine collection of multiple ground-state crystals. More generally, these results demonstrate: the incompleteness of atomic models; that single data sets contain insufficient information to model them fully; and that accuracy requires further map-deconvolution approaches.

-	~~Authors:~~ Pearce~~, N.M.~~, Krojer, T~~., Talon, R.~~, Bradley~~, A.R., Fairhead, M., Sethi, R., Wright, N., MacLean, E.~~, Collins, P., ~~Brandao-Neto~~, J., ~~Douangamath~~, ~~A., Renjie, Z., Dias, A., Ng~~, J., ~~Brennan~~, P.E.~~, Cox, O~~.~~, Bountra, C., Arrowsmith, C.H., Edwards, A., von Delft, F~~.	+	A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density.,Pearce NM, Krojer T, Bradley AR, Collins P, Nowak RP, Talon R, Marsden BD, Kelm S, Shi J, Deane CM, von Delft F Nat Commun. 2017 Apr 24;8:15123. doi: 10.1038/ncomms15123. PMID:28436492<ref>PMID:28436492</ref>

-	~~Description: PanDDA analysis group deposition~~ --~~Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: ~~Pearce~~, ~~N.M~~]]	+	<div class="pdbe-citations 5pzf" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Arrowsmith, C H]]
		+	[[Category: Bountra, C]]
		+	[[Category: Bradley, A R]]
		+	[[Category: Brandao-Neto, J]]
		+	[[Category: Brennan, P E]]
	[[Category: Collins, P]]		[[Category: Collins, P]]
	[[Category: Cox, O]]		[[Category: Cox, O]]
-	[[Category: ~~Arrowsmith, C.H]]~~	+	[[Category: Delft, F von]]
-	~~[[Category: Brandao-Neto, J]]~~	+	[[Category: Dias, A]]
-	~~[[Category: Fairhead, M]]~~	+
-	~~[[Category: Von~~ Delft, F]]	+
-	[[Category: ~~Renjie, Z]]~~	+
-	~~[[Category: Wright, N]]~~	+
-	~~[[Category: Ng, J]]~~	+
-	~~[[Category: Bradley, A.R]]~~	+
-	~~[[Category: Talon, R]]~~	+
-	~~[[Category: Brennan, P.E]]~~	+
-	~~[[Category: Edwards~~, A]]	+
	[[Category: Douangamath, A]]		[[Category: Douangamath, A]]
-	[[Category: ~~Maclean~~, E]]	+	[[Category: Edwards, A]]
		+	[[Category: Fairhead, M]]
	[[Category: Krojer, T]]		[[Category: Krojer, T]]
-	[[Category: ~~Dias~~, A]]	+	[[Category: MacLean, E]]
		+	[[Category: Ng, J]]
		+	[[Category: Pearce, N M]]
		+	[[Category: Renjie, Z]]
	[[Category: Sethi, R]]		[[Category: Sethi, R]]
-	[[Category: ~~Bountra~~, C]]	+	[[Category: Talon, R]]
		+	[[Category: Wright, N]]
		+	[[Category: Bromodomain]]
		+	[[Category: Epigenetic]]
		+	[[Category: Pandda]]
		+	[[Category: Sgc - diamond i04-1 fragment screening]]
		+	[[Category: Transcription]]
		+	[[Category: Xchemexplorer]]

OCA at 18:03, 15 March 2017

OCA — Wed, 15 Mar 2017 18:03:35 GMT

←Older revision		Revision as of 18:03, 15 March 2017
Line 3:		Line 3:
	The entry 5pzf is ON HOLD		The entry 5pzf is ON HOLD

-	Authors: Krojer, T.	+	Authors: Pearce, N.M., Krojer, T., Talon, R., Bradley, A.R., Fairhead, M., Sethi, R., Wright, N., MacLean, E., Collins, P., Brandao-Neto, J., Douangamath, A., Renjie, Z., Dias, A., Ng, J., Brennan, P.E., Cox, O., Bountra, C., Arrowsmith, C.H., Edwards, A., von Delft, F.

	Description: PanDDA analysis group deposition --Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)		Description: PanDDA analysis group deposition --Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
		+	[[Category: Pearce, N.M]]
		+	[[Category: Collins, P]]
		+	[[Category: Cox, O]]
		+	[[Category: Arrowsmith, C.H]]
		+	[[Category: Brandao-Neto, J]]
		+	[[Category: Fairhead, M]]
		+	[[Category: Von Delft, F]]
		+	[[Category: Renjie, Z]]
		+	[[Category: Wright, N]]
		+	[[Category: Ng, J]]
		+	[[Category: Bradley, A.R]]
		+	[[Category: Talon, R]]
		+	[[Category: Brennan, P.E]]
		+	[[Category: Edwards, A]]
		+	[[Category: Douangamath, A]]
		+	[[Category: Maclean, E]]
	[[Category: Krojer, T]]		[[Category: Krojer, T]]
		+	[[Category: Dias, A]]
		+	[[Category: Sethi, R]]
		+	[[Category: Bountra, C]]

OCA: Protected "5pzf" [edit=sysop:move=sysop]

OCA — Thu, 09 Mar 2017 13:15:44 GMT

Protected "5pzf" [edit=sysop:move=sysop]

←Older revision

Revision as of 13:15, 9 March 2017

OCA: New page: '''Unreleased structure''' The entry 5pzf is ON HOLD Authors: Krojer, T. Description: PanDDA analysis group deposition --Crystal Structure of SP100 after initial refinement with no lig...

OCA — Thu, 09 Mar 2017 13:15:42 GMT

New page: '''Unreleased structure''' The entry 5pzf is ON HOLD Authors: Krojer, T. Description: PanDDA analysis group deposition --Crystal Structure of SP100 after initial refinement with no lig...

New page

'''Unreleased structure'''

The entry 5pzf is ON HOLD

Authors: Krojer, T.

Description: PanDDA analysis group deposition --Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)
[[Category: Unreleased Structures]]
[[Category: Krojer, T]]